A multi‐omics perspective of CAR T cell therapy

As omics technologies, including genomics, epigenomics, transcriptomics, T cell receptor‐repertorie profiling, proteomics, metabolomics and microbiomics, have provided valuable insights into CAR T cell therapy, in our recent review, we discuss these multidimensional profiling technologies in CAR T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jingwen, Chen, Yamei, Han, Leng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212274/
https://www.ncbi.nlm.nih.gov/pubmed/37228183
http://dx.doi.org/10.1002/ctm2.1274
_version_ 1785047429779816448
author Yang, Jingwen
Chen, Yamei
Han, Leng
author_facet Yang, Jingwen
Chen, Yamei
Han, Leng
author_sort Yang, Jingwen
collection PubMed
description As omics technologies, including genomics, epigenomics, transcriptomics, T cell receptor‐repertorie profiling, proteomics, metabolomics and microbiomics, have provided valuable insights into CAR T cell therapy, in our recent review, we discuss these multidimensional profiling technologies in CAR T cell research, and their potential to identify tumor‐specific antigens and molecular characteristics associated with anti‐tumour effects and toxicities.
format Online
Article
Text
id pubmed-10212274
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102122742023-05-26 A multi‐omics perspective of CAR T cell therapy Yang, Jingwen Chen, Yamei Han, Leng Clin Transl Med Commentary As omics technologies, including genomics, epigenomics, transcriptomics, T cell receptor‐repertorie profiling, proteomics, metabolomics and microbiomics, have provided valuable insights into CAR T cell therapy, in our recent review, we discuss these multidimensional profiling technologies in CAR T cell research, and their potential to identify tumor‐specific antigens and molecular characteristics associated with anti‐tumour effects and toxicities. John Wiley and Sons Inc. 2023-05-25 /pmc/articles/PMC10212274/ /pubmed/37228183 http://dx.doi.org/10.1002/ctm2.1274 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Yang, Jingwen
Chen, Yamei
Han, Leng
A multi‐omics perspective of CAR T cell therapy
title A multi‐omics perspective of CAR T cell therapy
title_full A multi‐omics perspective of CAR T cell therapy
title_fullStr A multi‐omics perspective of CAR T cell therapy
title_full_unstemmed A multi‐omics perspective of CAR T cell therapy
title_short A multi‐omics perspective of CAR T cell therapy
title_sort multi‐omics perspective of car t cell therapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212274/
https://www.ncbi.nlm.nih.gov/pubmed/37228183
http://dx.doi.org/10.1002/ctm2.1274
work_keys_str_mv AT yangjingwen amultiomicsperspectiveofcartcelltherapy
AT chenyamei amultiomicsperspectiveofcartcelltherapy
AT hanleng amultiomicsperspectiveofcartcelltherapy
AT yangjingwen multiomicsperspectiveofcartcelltherapy
AT chenyamei multiomicsperspectiveofcartcelltherapy
AT hanleng multiomicsperspectiveofcartcelltherapy

Ejemplares similares